Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
Rhea-AI Summary
Immix Biopharma (NASDAQ:IMMX), a clinical-stage biopharmaceutical company, has secured a strategic investment from Goose Capital, led by former Tanox CEO Dr. Nancy T. Chang. Dr. Chang's track record includes developing successful FDA-approved drugs like XOLAIR®, TROGARZO®, and EBGLYSS®, which have collectively generated over $5 billion in sales.
The investment aims to support Immix's development of cell therapies for AL Amyloidosis and other serious diseases, particularly the commercialization of NXC-201 for relapsed/refractory AL Amyloidosis. This strategic partnership brings valuable expertise to Immix, as Dr. Chang has significant experience in bringing drugs from invention through FDA approval and commercialization.
Positive
- Strategic investment secured from experienced biotech investor Goose Capital
- Partnership with Dr. Nancy T. Chang, who has track record of developing drugs with $5B+ in sales
- Addition of valuable expertise in FDA approval and drug commercialization process
Negative
- Early clinical-stage company with no approved products yet
- Specific investment amount not disclosed
News Market Reaction – IMMX
On the day this news was published, IMMX gained 5.07%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.2% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $67M at that time.
Data tracked by StockTitan Argus on the day of publication.
LOS ANGELES, CA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it has received a strategic investment from Goose Capital and former Tanox, Inc. CEO Dr. Nancy T. Chang, Goose founding member.
At Tanox, Dr. Chang and her team invented and developed FDA-approved XOLAIR® (omalizumab) for severe asthma, TROGARZO® (ibalizumab-uiyk) for HIV, and EBGLYSS® (lebrikizumab-lbkz) for dermatitis, collectively generating drug sales exceeding 5 billion dollars so far. Tanox, Inc. was acquired by Genentech/Roche. EBGLYSS® is commercialized by Eli Lilly and Co.
“Immix’s mission of curing the incurable resonates with Goose’s goal of investing in breakthrough technologies and innovative founders to forge the future of human medicine,” said Anthony George, President of Goose Capital. Ashok Rao, Board Member of Goose Capital, added, “After a deep evaluation of the technology, team, and market that Immix is pursuing, we are pleased to support, and anticipate exciting progress to-come.”
“We are thrilled that Dr. Chang and Goose recognize the opportunity for commercialization of NXC-201 in relapsed/refractory AL Amyloidosis, other serious diseases, and beyond,” said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, “Goose and Dr. Chang bring unparalleled experience to the Immix team. Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, further enabling our goal to deliver widely accessible cures, as patients are waiting.”
About Goose Capital
Goose Capital is an investment firm comprised of former Fortune 500 executives, industry leaders, and serial entrepreneurs. Goose Capital invests in breakthrough technologies, early-stage startups and innovative founders.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that filters out non-specific activation. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NEXICART-2 primary endpoint was met at interim results presented at ASCO 2025. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com.
Forward Looking Statements
This press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, the potential benefits of our product candidate CAR-T NXC-201 and the timing and results related clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1/2 clinical trials for CAR-T NXC-201 will not be favorably consistent with the data readouts to date, (ii) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (iii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iv) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (v) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (vi) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2025 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Company Contact
irteam@immixbio.com
FAQ
What is the strategic investment Immix Biopharma (IMMX) received in September 2025?
Who is Dr. Nancy T. Chang and why is her involvement significant for IMMX?
What is Immix Biopharma's main development focus?
How does this investment align with Goose Capital's investment strategy?
